Md Nurunnabi

Campbell Building
El Paso Texas, 79968
Phone Logo(915) 747-8335
HomeWeb Site




Md Nurunnabi
Assistant Professor, Pharmacy

Md Nurunnabi is an Assistant Professor in School of Pharmacy at University of Texas at El Paso. Dr. Nurunnabi has been trained in both the Pharmaceutical and the Bioengineering fields. Over the past decade I received training in biomaterials, nanotechnology, drug delivery, biomedical imaging, histology and pathology. Nurunnabi received his PhD in Bioengineering in 2015 from The Korea National University of Transportation, in South Korea. He later did two postdoctoral trainings in bioengineering, one in the Chungnam National University, in South Korea and another in Harvard University, in Massachusetts. He was also a pre-doctoral fellow in Bioengineering and Pharmaceutics at the University of Utah, after completing a Masters in Chemical and Biological Engineering. In addition to his academic research, Dr. Nurunnabi been involved in industrial research. He was co-founder and chief scientist at the KB BioMed Inc., in South Korea and an Associate Scientist in Chunbo Corporation Ltd, also in South Korea. My research has resulted over 44 peer-reviewed journal articles, 8 book chapters, and 10 patent applications (issued/pending). Several of Dr. Nurunnabi's patents have been licensed and resulted in a start-up company. In the fall of 2019 Dr. Nurunnabi started his first independent faculty position as a tenure-track Assistant Professor in the Department of Pharmaceutical Science at University of Texas at El Paso (UTEP). However, his research trajectory started soon after completing my undergraduate degree in Pharmacy, when he started working on the synthesis of different emission-based quantum dots for target-specific imaging of tumor in deep tissue and organs and target-specific drug delivery by actively targeting cell receptors. Around a decade ago, his research group developed a platform technology for oral delivery of semiconductor quantum dots. semiconductor quantum dots had been found to be one of the most fascinating and emerging candidates for biomedical diagnosis through optical spectroscopy for detecting various diseases through noninvasive imaging techniques. Over the years Dr. Nurunnabi gained expertise in synthesizing iron oxide nanoparticles as MRI contrast agent, gold nanoparticles for drug delivery and photothermal therapy and photoluminescent graphene nanoparticles for in vitro and in vivo optical imaging and 2D boron nitride for biosensing of dopamine content in body fluid. He has also learned different techniques and strategies for modifying and decorating surfaces of graphene with biocompatible polymers that enhances retention time in blood circulation. An additional area of expertise is that of Biomaterials. Dr. Nurunnabi's expertise lies in developing soft materials for various biomedical applications such as hyaluronic acid gel for controlling drug release in implant, hyaluronic acid-pluronic based elastic hydrogel for cardiac tissue regeneration, natural hydrogel for wound healing and hydroxyapatite-based gel for osteoporosis treatment and bone tissue regeneration.One of his key research areas is oral drug delivery of large molecules such as peptide, protein, and antibody. Dr. Nurunnabi's research aims are to address the key barriers in oral drug delivery that includes, stability in GIT and penetrating mucosal barrier. Previously, he had developed a bile acid mediated oral delivery platform that showed highly effective in cancer animal model and maintain commutive PK and PD of the anticancer drug Docetaxel. Later on, Dr. Nurunnabi has expanded the technology to investigate feasibility of GLP1 oral delivery to treat type-2 diabetes. He also designed an M-cell targeting nanoparticle to oral delivery of PR8 protein as an immunomodulator. Recently they have reported an oral ionic liquid that has potential in treating obesity by reducing fat uptake through intestine. Recently his research group developed a series of peptide-based formulation to target the biomarkers of lung fibrosis, scleroderma, arthritis and intestinal inflammation and optimized the formulation for noninvasive imaging and targeting therapy of the disease.


  1. Biomaterials
  2. Drug delivery
  3. Bio-nanomaterials
  4. Image guided therapy